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Background-—Proprotein convertase subtilisin/kexin type 9 (PCSK9) circulating levels are signiﬁcantly associated with an
increased risk of cardiovascular events. This study aimed to evaluate the relationship between circulating levels of PCSK9 and
arterial stiffness, an early instrumental biomarker of cardiovascular disease risk, in a large sample of overall healthy participants.
Methods and Results-—From the historical cohort of the Brisighella Heart Study, after exclusion of active smokers, participants in
secondary prevention for cardiovascular disease, and patients in treatment with statins or vasodilating agents, we selected 227
premenopausal women and 193 age-matched men and 460 postmenopausal women and 416 age-matched men. In these
participants, we evaluated the correlation between PCSK9 plasma circulating levels and pulse wave velocity. Postmenopausal
women showed higher PCSK9 levels (309.984.1 ng/mL) compared with the other groups (P<0.001). Older men had signiﬁcant
higher levels than younger men (283.275.6 versus 260.980.4 ng/mL; P=0.008). In the whole sample, pulse wave velocity was
predicted mainly by age (B=0.116, 95% CI 0.96–0.127, P<0.001), PCSK9 (B=0.014, 95% CI 0.011–0.016, P<0.001), and serum uric
acid (B=0.313, 95% CI 0.024–0.391, P=0.026). Physical activity, low-density lipoprotein cholesterol, high-density lipoprotein
cholesterol, and estimated glomerular ﬁltration rate were not associated with pulse wave velocity (P>0.05).By considering the
subgroups described, age and PCSK9 levels were mainly associated with pulse wave velocity, which also correlated with serum uric
acid in postmenopausal women.
Conclusions-—In the Brisighella Heart Study cohort, circulating PCSK9 is signiﬁcantly related to arterial stiffness, independent of
sex and menopausal status in women. ( J Am Heart Assoc. 2017;6:e005764. DOI: 10.1161/JAHA.117.005764.)
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P roprotein convertase subtilisin/kexin type 9 (PCSK9) issecreted mainly by liver, and its serum concentration
depends on its own synthesis, processing, and clearance.1
The best characterized activity of PCSK9 is the posttransla-
tional regulation of low-density lipoprotein (LDL) receptor
expression.2 In fact, PCSK9 increases serum concentrations
of LDL cholesterol (LDL-C) by inducing LDL receptor
degradation, increases intestinal triglyceride-rich lipoprotein
production and secretion through transcriptional and post-
transcriptional mechanisms,3 and, ﬁnally, enhances triglyc-
eride accumulation by targeting the very LDL receptor in the
adipose tissue.4,5 Some experimental studies showed PCSK9
to be signiﬁcantly expressed in vascular smooth muscle cells
as well as in human atherosclerotic plaques6 and to be
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involved in neointima formation.7 A 100 ng/mL increase in
PCSK9 was related to an increase in total plaque area.8
Moreover, PCSK9 was associated with carotid intima–media
thickness in familial hypercholesterolemic and hypertensive
patients.9,10
A widely used parameter for an indirect assessment of
arterial stiffness is pulse wave velocity (PWV), or rather the
propagation speed of the pulse pressure wave, which
predicts the adverse cardiovascular events in hypertension
and cardiovascular disease (CVD).10 A positive correlation
between arterial stiffness and end-organ damage was
clearly established in CVD.11 Because the plaque compo-
nents are responsible for arterial stiffness, increment of
intima–media thickness, and atherosclerosis,12 the obser-
vation that PCSK9 is expressed in the atherosclerotic
plaque7 could open new avenues of study on the role of
PCSK9 on arterial wall remodeling. Nevertheless, to the
best of our knowledge, no association has been studied
between circulating PCSK9 and arterial stiffness in the
general population.
Based on these premises, the present study aimed to
evaluate the relationship between circulating levels of PCSK9
and arterial stiffness in a large sample of overall healthy
participants.
Methods
Participants
The Brisighella Heart Study is a longitudinal population study
on a randomized sample representative of the entire
population of Brisighella, a rural northern Italian village. The
study has been active since 1972 and is carried out in
agreement with the Declaration of Helsinki.13 The protocol
was approved by the institutional ethics board of the
University Hospital of Bologna. The complete version of the
protocol and the history of the study have been extensively
described elsewhere. All participants gave written informed
consent to participate.
For the present analysis, we selected from the general
database of the Brisighella Heart Study 227 premenopausal
women and 193 age-matched men and 460 post-
menopausal women and 416 age-matched men, excluding
participants who were active smokers, who were known to
have carotid atherosclerosis,14 or who were in secondary
prevention for CVD or in treatment with statins or
vasodilating agents. Menopause was self-deﬁned by the
interviewed patients as the moment when menstruation
deﬁnitively stopped and was conﬁrmed with their general
practitioners’ clinical forms. All available routine clinical and
laboratory parameters were sampled with standardized
methods.15,16 Estimated glomerular ﬁltration rate (eGFR)
was calculated using the CKD-EPI (Chronic Kidney Disease
Epidemiology Collaboration) formula.17 In particular, con-
ventional blood pressure was measured after 10 minutes of
rest in the seated position within a half hour of obtaining
blood samples and in the arm opposite that used for
venesection. These measurements were obtained by a
trained nurse using a mercury sphygmomanometer and an
appropriately sized cuff according to the European Society
of Hypertension guidelines.18
PCSK9 Measurement
PCSK9 was blindly measured using a commercial ELISA kit
(R&D Systems) with plasma aliquot collected after overnight
fasting and stored at 80°C, by as previously described.19
The minimum detectable dose ranged from 0.030 to
0.219 ng/mL, with a mean concentration of 0.096 ng/mL.
Arterial Stiffness Evaluation
Arterial stiffness parameters were assessed using the
Vicorder apparatus (Skidmore Medical Ltd), a validated cuff-
based device that estimates central blood pressure using a
brachial-to-aortic transfer function.
PWV consists of the measurement of the pulse wave
transmission through the arteries and is considered a reliable
and early marker of arterial stiffness and a predictor of
cardiovascular risk.20 The theoretical basis of PWV is
explained with the equation of Moens–Korteweg,21 whereas
in clinical practice, PWV is calculated as the length between 2
measurement sites divided by the time the pulse wave needs
to cover that distance (m/s).22
Augmentation index is obtained through the blood pres-
sure waveform analysis. It represents, as well as PWV, a
measure of wave reﬂection and arterial stiffness and a marker
of cardiovascular risk.20 It is calculated as the ratio of the
pressure increment caused by the reﬂected wave (augmented
pressure) to the pulse pressure.23
Pulse wave analysis, from which the augmentation index is
obtained, is recorded simply with a brachial cuff placed at the
patient’s right arm: The Vicorder apparatus registers the radial
pressure and, with a speciﬁc algorithm, derives the central
blood pressure curve. PWV is calculated with a simultaneous
measurement of carotid and femoral blood pressure. A small
neck pad containing a photoplethysmographic detector is
placed around the neck, and a normal cuff is positioned
around the thigh of the patient. The distance between the
suprasternal notch and the thigh cuff is measured with a
measuring tape. This length represents the distance covered
by the pulse wave in its carotid–femoral path and is used by
the Vicorder apparatus to establish the PWV value.24,25 The
Vicorder system automatically adjusts the PWV measurement
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for heart rate and mean artery pressure, as they are
simultaneously recorded.
Statistical Analysis
A full descriptive analysis was performed of all considered
variables. The Kolmogorov–Smirnov normality test was
performed for the continuous variables. The continuous
variables were compared among the different renal function
classes by ANOVA followed by the Tukey post hoc test.
Nonnormally distributed parameters were then log-trans-
formed before continuing with further analyses. First, we
carried out a bivariate correlation for age, LDL-C, high-
density lipoprotein cholesterol, serum uric acid (SUA), eGFR,
and PWV. Then, we performed a multiple linear regression
analysis using PWV as a dependent variable and age,
physical activity, LDL-C, high-density lipoprotein cholesterol,
PCSK9, SUA, and eGFR as independent variables. The
analysis was ﬁnally repeated by the predeﬁned participant
categories (younger and older men, premenopausal and
postmenopausal women). All tests were carried out using
SPSS 21.0 for Windows (IBM Corp). A signiﬁcance level of
0.05 was considered for every test.
All data are available at the research center under the
responsibility of Professor Claudio Borghi.
Results
The main anagraphic, anthropometric, hemodynamic, and
laboratory characteristics of the subgroup participants are
described in Table 1. As expected, there was a speciﬁc age
and sex distribution of the main CVD risk factors. Among
them, LDL-C was signiﬁcantly higher in postmenopausal
versus premenopausal women, whereas similar concentra-
tions were observed between younger and older men. Waist
circumference, blood pressure, triglycerides, fasting plasma
glucose, and SUA were signiﬁcantly higher in older partici-
pants than in younger ones. High-density lipoprotein choles-
terol was signiﬁcantly lower in men than in women,
independent of age. From a clinical point of view, the most
relevant ones are the increase of pulse pressure and the
decrease of eGFR in older participants.
As reported in Figure, postmenopausal women showed
higher PCSK9 levels (309.984.0 ng/mL) compared with
premenopausal women (269.478.8 ng/mL; P<0.001)
and the other groups of participants (P<0.001). Older
men had signiﬁcantly higher levels than younger men
(283.275.8 versus 260.980.4 ng/mL; P=0.008).
In the univariate model, circulating PCSK9 levels were
related to age (r=0.180, P<0.001), systolic blood pressure
(r=0.138, P<0.001), pulse pressure (r=0.143, P<0.001), mean
Table 1. Main Characteristics of the Selected Participants
Premenopausal
Women (n=227)
Younger Men
(n=193)
Postmenopausal
Women (n=460)
Older Men
(n=416)
Age, y 41.08.4 40.37.7 66.810.6* 67.259.8*
WC, cm 80.915.9 92.511.1 90.315.4* 98.514.5*†
Heart rate, bpm 67.312.2†‡ 61.611.5†‡ 65.811.9†‡ 61.511.4†‡
SBP, mm Hg 127.414.5 131.313.1† 148.013.5* 145.711.9*
DBP, mm Hg 68.88.6 72.49.5† 73.410.1* 76.99.5*
Pulse pressure, mm Hg 58.510.9 58.99.8 74.610.4* 68.710.8*†
MAP, mm Hg 94.310.9 95.911.2 104.713.9* 104.911.9*
TC, mg/dL 208.136.8 209.236.3 227.340.2 215.840.2
Triglycerides, mg/dL 95.962.4 118.276.8† 119.557.9* 131.078.7*
HDL-C, mg/dL 55.45.4 48.44.5† 54.35.5 48.04.7†
LDL-C, mg/dL 132.925.8 136.424.4 148.628.8* 135.630.5
Lipoprotein(a), mg/dL 17.415.6 19.317.6 26.322.0* 20.418.1†
FPG, mg/dL 87.217.1 90.59.8 95.116.7* 101.915.9*†
SUA, mg/dL 4.31.0 5.71.1† 4.91.2* 6.01.2†
eGFR, mL/min 79.113.5 85.912.8† 63.514.1* 68.713.4*†
DBP indicates diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate (CKD-EPI [Chronic Kidney Disease Epidemiology Collaboration] equation); FPG, fasting plasma glucose;
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MAP, mean arterial pressure; SBP, systolic blood pressure; SUA, serum uric acid; TC, total
cholesterol; WC, waist circumference.
*P<0.05 vs same sex, younger category.
†P<0.05 vs same age class, other sex.
‡P<0.001 vs other age class, other sex.
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arterial pressure (r=0.116, P<0.001), total cholesterol
(r=0.159, P<0.001), triglycerides (r=0.178, P<0.001), LDL-C
(r=0.089, P=0.001), SUA (r=0.060, P=0.030), fasting
plasma glucose (r=0.107, P<0.001), lipoprotein(a) (r=0.100,
P<0.001), eGFR (r=0.101, P<0.001), and carotid–femoral
PWV (r=0.302, P<0.002).
The multiple linear regression model carried out on the
whole population sample showed that PWV was predicted
mainly by age (B=0.114, 95% CI 0.92–0.129, P<0.001),
PCSK9 (B=0.027, 95% CI 0.021–0.033, P<0.001), and SUA
(B=0.301 95% CI 0.022–0.388, P=0.029). Physical activity,
LDL-C, high-density lipoprotein cholesterol, and eGFR were
not signiﬁcantly associated with PWV (P>0.05).
The signiﬁcant predictors of PWV in the different sub-
groups were reported in Table 2. Age and PCSK9 were the
main factors associated with PWV, which also correlated with
SUA but only in postmenopausal women.
Discussion
The present study, carried out in a large sample of overall
healthy participants not in treatment with vasoactive medi-
cations, showed that circulating PCSK9 tends to increase with
age regardless of sex and was signiﬁcantly more elevated in
women independent of menopausal condition. These effects
agree with previous ﬁndings reporting that PCSK9 levels
increase in women reaching menopause but not in older
men.26 Whether age could affect the PCSK9 levels remains an
open question because PCSK9 concentrations are partly
related to growth hormone serum levels, as reported by
Persson et al.27
In our population sample, as emerged from the univariate
analysis, the circulating levels of PCSK9 were related to a
large number of CVD risk factors, namely, age, systolic blood
pressure, pulse pressure, mean arterial pressure, LDL-C,
triglycerides, SUA, fasting plasma glucose, lipoprotein(a),
eGFR, and carotid–femoral PWV. Most of these correlations
are in line with previous ﬁndings showing how PCSK9 levels
positively correlate with LDL-C, with non–statin-treated
patients,28 with lipoprotein(a),29 and with atherogenic lipopro-
teins in patients with high cardiovascular risk.30
Figure. Serum proprotein convertase subtilisin/kexin type 9
(PCSK9) level (ng/mL; mean, 95% CI) in the study population.
*P<0.001 vs all other groups; P=0.008 for older men vs younger
men.
Table 2. Signiﬁcant Predictors of Pulse Wave Velocity in the Different Subgroups
Predictor
Premenopausal Women Postmenopausal Women
B
95% CI
P Value B
95% CI
P ValueLower Limit Upper Limit Lower Limit Upper Limit
Age 0.144 0.98 0.213 <0.001 0.225 0.135 0.316 0.003
PCSK9 0.021 0.008 0.031 0.002 0.036 0.026 0.045 <0.001
SUA >0.05 0.496 0.088 0.901 0.017
Predictor
Younger Men Older Men
B
95% CI
P Value B
95% CI
P ValueLower Limit Upper Limit Lower Limit Upper Limit
Age 0.162 0.084 0.290 0.002 0.258 0.165 0.342 <0.001
PCSK9 0.029 0.018 0.046 <0.001 0.028 0.015 0.039 <0.001
SUA >0.05 >0.05
Independent variables: age, physical activity, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, PCSK9, SUA, and estimated glomerular ﬁltration rate (CKD-EPI
[Chronic Kidney Disease Epidemiology Collaboration] equation). PCSK9 indicates proprotein convertase subtilisin/kexin type 9; SUA, serum uric acid.
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Circulating levels of PCSK9 and vascular aging (evaluated
in term of carotid intima–media thickness) were recently
studied with conﬂicting results in hypertensive patients.10 In
contrast, circulating PCSK9 was found to be an independent
predictor of carotid arteriosclerosis in asymptomatic adults.31
Our ﬁndings showed that PCSK9 is signiﬁcantly associated
with arterial stiffness (estimated in term of carotid–femoral
PWV) regardless of sex and, in women, menopausal condition.
The strength of this association was very high from a
statistical point of view but relatively weak in absolute terms.
However, because small differences in arterial stiffness seem
to be associated with clinically signiﬁcant differences in CVD
risk, our observation should not be underestimated.12 More-
over, PCSK9 is measurable with a standardized method, and
its circulating level is related to its tissue concentration.19
A relatively large number of clinical studies clearly
documented the feasibility of using monoclonal antibodies
against PCSK9, alone or in combination with statins, to
achieve very low LDL-C levels.32 Waiting for long-term trial
results on morbidity and mortality data, the recent ﬁndings
from the GLAGOV (GLobal Assessment of Plaque reGression
With a PCSK9 antibOdy as Measured by intraVascular
Ultrasound) study demonstrated the efﬁcacy of evolocumab
on reducing progression of atherosclerosis as measured by
intravascular ultrasound.33 Additional evidence suggested a
direct role of PCSK9 on atherosclerotic plaque formation
independent of the LDL-C lowering effect. In particular, the
ATHEROREMO-IVUS study showed that higher serum PCSK9
levels are linearly associated with a higher necrotic core
fraction in coronary atherosclerosis, regardless of serum LDL-
C.34 In line with this evidence, a signiﬁcant association
between serum PCSK9 levels and intima–media thickening
was reported in hypertensive patients and persisted after
adjustment for blood lipids.10 Furthermore, Werner et al
demonstrated in a prospective cohort study that elevated
PCSK9 serum concentrations were associated with cardio-
vascular events in patients with stable coronary artery
disease, despite a well-controlled LDL-C concentration.35
Consequently, serum PCSK9 levels seem to predict early
atherosclerosis and potentially involve plaque development
and composition. By using an experimental model of carotid
restenosis, our research group recently demonstrated that
PCSK9/ mice are partially protected from neointimal
formation, further supporting the positive effect of PCSK9
on intimal thickening.7
At the same time, SUA, which is the ﬁnal end product of
purine catabolism, is considered a CVD risk factor36 and, in
healthy persons, an early marker of vascular stiffness.37 The
association between SUA and PWV was previously studied in
the Brisighella Heart Study cohort.14,16 Nevertheless, it is
interesting to note in the present analysis that SUA did not
affect the correlation between PCSK9 and PWV.
The main limitation of this study was the relatively small
size of the single predeﬁned groups; however, this was
representative of the participants’ distribution in the Brisigh-
ella Heart Study cohort. Moreover, the considered sample
included more participants than a large part of the previously
published paper investigating the association between circu-
lating PCSK9 and arterial aging. Another limitation is the
selection of the participants, which could have introduced a
bias; however, a large number of the participants that we
excluded from the analysis had characteristics that could
affect the measurement of PWV and, consequently, the
reliability of our observations. A further limitation regards the
evaluation of menopausal age, which was based on patient
self-reporting of menstruation cessation and not on speciﬁc
laboratory parameters; however, data were conﬁrmed by
comparison with the information included in the general
practitioner clinical forms.
Based on the assumptions that PCSK9 levels are associ-
ated with increased risk of total cardiovascular events38 and
that variants in genes encoding PCSK9, leading to decreased
LDL-C levels, are protective for the risk of CVD events,39 our
results support the hypothesis that an increment in circulating
PCSK9 levels could be associated with arterial stiffness
independent of atherogenic lipoproteins levels and a possible
early marker of cardiovascular risk in overall healthy persons.
In conclusion, in an overall healthy population sample,
circulating PCSK9 seems to be signiﬁcantly related to arterial
stiffness independent of sex and, in women, menopausal
status.
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